Skip to content
Toggle main navigation
GMSLinked logo
GMSLinked logo
  • Events
  • Community
  • Events
  • Knowledge Hub
    Log in
    Request to join

    News

    Filter by category
    All
    Biotechnology
    Engineering
    Industrial IOT
    Maintenance, Reliability & Operations
    Manufacturing
    Pharmaceuticals
    Supply Chain

    Highlighted news

    Search results (49)

    Abu Dhabi DoH signs new deal to accelerate development in life sciences

    Abu Dhabi DoH signs new deal to accelerate development in life sciences

    The Department of Health Abu Dhabi (DoH) has made a declaration of collaboration with Mass General Brigham’s (MGB) International Center for Genetic Disease (iCGD) to advance life sciences.The deal is aimed at advancing life sciences across three strategic areas: clinical and translational research, capacity building and technology transfer, and in the area of commercialisation.Benefiting from Abu
    16 June 2023
    Pfizer and GSK to battle for share of new RSV vaccine market

    Pfizer and GSK to battle for share of new RSV vaccine market

    With both GSK and Pfizer recently gaining FDA approval for their respective respiratory syncytial virus (RSV) vaccines, the stakes are high for competition in the sector.
    16 June 2023
    Beacon Therapeutics enters gene therapy arena with $120m launch

    Beacon Therapeutics enters gene therapy arena with $120m launch

    Beacon Therapeutics has kickstarted its entry into the gene therapy field with a $120m Series A financing.The British investment trust Syncona Limited launched the new ophthalmic gene therapy company by combining Applied Genetic Technologies Corporation’s (AGTC’s) late-stage X-linked retinitis pigmentosa (XLRP) programme with two proprietary preclinical programmes.The funding, with participation f
    16 June 2023
    World’s largest lutetium-177 production site opens

    World’s largest lutetium-177 production site opens

    A new therapeutic radionuclide facility, the world’s largest production site of lutetium-177, has opened in Germany. ITM Isotope Technologies Munich SE (ITM)’s manufacturing plant in Neufahrn near Munich will produce the innovative medical isotope for targeted cancer therapies.“Radiopharmaceuticals are an essential new class of anti-cancer drugs that have the potential to improve therapy outcomes
    16 June 2023
    Novo Nordisk to invest $2.3bn to expand Danish manufacturing facilities

    Novo Nordisk to invest $2.3bn to expand Danish manufacturing facilities

    Novo Nordisk has unveiled plans to make a DKr15.9bn ($2.29bn) investment, starting from 2023, to expand its manufacturing facilities in Hillerød, Denmark.The new investment will create additional production capacity, increase the company’s capacity to meet future demand and enable the development of its future clinical late-phase product portfolio.The investment will be used for expanding its exis
    16 June 2023
    AstraZeneca announces agreement with Quell Therapeutics to develop, manufacture and commercialise engineered T-regulatory cell therapies for autoimmune diseases

    AstraZeneca announces agreement with Quell Therapeutics to develop, manufacture and commercialise engineered T-regulatory cell therapies for autoimmune diseases

    AstraZeneca has entered into an exciting collaboration, exclusive option and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies that have the potential to be curative in Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD) indications.Under the terms of the agreement, Quell's proprietary toolbox of Treg cell engineering modules, includi
    16 June 2023
    Owkin invests  $50M in spatial omics project that will 'revolutionize cancer research'

    Owkin invests $50M in spatial omics project that will 'revolutionize cancer research'

    Artificial intelligence (AI) biotech company, Owkin, has invested $50million in a project that will use spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors.
    16 June 2023
    Quell Therapeutics and AstraZeneca partner on Treg cell therapies

    Quell Therapeutics and AstraZeneca partner on Treg cell therapies

    Quell Therapeutics and AstraZeneca have entered a collaboration, exclusive option and licence deal for the development, manufacturing and commercialisation of engineered T-regulator (Treg) cell therapies for autoimmune diseases.The collaboration will combine the multi-modular Treg cell engineering and manufacturing expertise of Quell and AstraZeneca’s developmental, commercial and therapeutic capa
    16 June 2023
    Novo Nordisk invests €2.1bn in Hillerød manufacturing expansion

    Novo Nordisk invests €2.1bn in Hillerød manufacturing expansion

    Novo Nordisk intends to invest 15.9 billion Danish kroner (€2.1 billion) to expand an existing active pharmaceutical ingredient (API) production facility in Hillerød, Denmark.The investment, which begins in 2023, will create additional production capacity and increase Novo Nordisk’s ability to meet future market demands.“This important investment will ensure the continuous development of our late-
    16 June 2023
    Bristol Myers Squibb gains FDA approval for production at new facility

    Bristol Myers Squibb gains FDA approval for production at new facility

    The US Food and Drug Administration (FDA) has granted approval to commence commercial production at Bristol Myers Squibb’s new advanced cell therapy manufacturing facility in Devens, Massachusetts.The new 244,000ft² facility represents Bristol Myers Squibb’s third commercial CAR T [chimeric antigen receptor T-cell] manufacturing facility in the country and the second significant expansion of its 8
    16 June 2023
    Pfizer and Samsung Biologics ink biosimilars manufacturing deal

    Pfizer and Samsung Biologics ink biosimilars manufacturing deal

    Samsung Biologics, the South Korean contract development and manufacturing organisation (CDMO), has entered into a strategic partnership for the long-term commercial manufacturing of Pfizer’s multi-product biosimilars portfolio. Under the deal, Samsung Biologics said it will provide Pfizer with “additional capacity for large-scale manufacturing of a multi-product biosimilars portfolio covering onc
    16 June 2023
    Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics

    Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics

    Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas' LNP technology will support Bayer's in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.
    16 June 2023
    Viona Pharmaceuticals Inc., Issues Voluntary Nationwide Recall of Metformin HCl Extended- Release Tablets, USP 750 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity

    Viona Pharmaceuticals Inc., Issues Voluntary Nationwide Recall of Metformin HCl Extended- Release Tablets, USP 750 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity

    Cranford, New Jersey, Viona Pharmaceuticals Inc., is voluntarily recalling thirty three (33) lots of Metformin Hydrochloride Extended-Release Tablets, USP 750 mg to the retail level. Reason for the recall is an Out of specification result observed for the said product, Lot number M008132, “N-nitroso
    16 June 2023
    Axol and StrataStem link up for Alzheimer’s disease trial

    Axol and StrataStem link up for Alzheimer’s disease trial

    Companies will incorporate cells and technology to create a ‘clinical trial in a dish’
    16 June 2023
    Samsung Biologics speeds up $1.5 billion fifth plant, CEO reveals at BIO 2023

    Samsung Biologics speeds up $1.5 billion fifth plant, CEO reveals at BIO 2023

    Samsung Biologicsâ upcoming fifth plant will be operational by April 2025, five months earlier than previously expected, the biotech company revealed at BIO International Convention on Monday 5.
    16 June 2023
    Encouraging results for Parkinson's Disease drug in Biovie study as more patients retain sufficient muscle control

    Encouraging results for Parkinson's Disease drug in Biovie study as more patients retain sufficient muscle control

    Encouraging clinical data has been released by Biovie, a company developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.
    16 June 2023
    Whitepaper: Informatica-Cognizant enabling data-driven transformation in life sciences

    Whitepaper: Informatica-Cognizant enabling data-driven transformation in life sciences

    Life sciences firms have always been at the forefront of technology adoption. The industry’s embrace of digital has been a catalyst for incredible change: accelerating innovation, getting products to market faster, growing market share, and improving efficiency.
    16 June 2023
    Selvita and the University of Oxford join forces to tackle Parkinson’s disease

    Selvita and the University of Oxford join forces to tackle Parkinson’s disease

    The Polish drug discovery and service provider Selvita has announced a new collaboration with the University of Oxford to advance the development of Parkinson’s disease therapies.Parkinson’s is caused by a build-up of alpha-synuclein, a small protein, forming aggregates inside vulnerable neurons. Cells are then unable to efficiently clear these aggregates, potentially killing neurons and allowing
    16 June 2023
    Eikon Therapeutics bag $106m to fund eager acquisitions

    Eikon Therapeutics bag $106m to fund eager acquisitions

    San Francisco-based biotech Eikon Therapeutics has made waves in the bay after managing to raise $106m in its Series C funding round.This latest cash injection will be used to fund and support a range of acquisitions intended to diversify their development pipeline, which were announced alongside the fundraise, as per a 1 June announcement.The company acquired the global rights to develop and comm
    16 June 2023
    BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910

    BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910

    BI-1910 is now the second of the company's anti-tumour necrosis factor receptor 2 programmes to enter clinical development
    16 June 2023
    Contact
    GMSLinked
    231-232 Strand Temple London WC2R 1DA United Kingdom
    info@gmstrats.com
    +44 (0) 207 952 6111
    Cookies
    Withdraw cookie consent
    Community engagement platform by Hivebrite.